John Carroll

Some, though cer­tain­ly not all, chief in­di­ca­tors of biotech busi­ness ac­tiv­i­ty are point­ed shak­i­ly north as we head in­to a crit­i­cal Q4. But biotech shows

Bioreg­num Opin­ion Col­umn by John Car­roll It all start­ed to look se­ri­ous­ly bad when my legs be­gan to swell up, which I ini­tial­ly — stu­pid­ly

I’ve got a query for you to­day. Do you know a tru­ly great pri­vate biotech out there with out­stand­ing man­age­ment, su­per sci­ence, am­bi­tious and nov­el

Aviv Regev When Aviv Regev closed out one long chap­ter of her life at the Broad and stepped in­to a new job as head of

Back in 2013, Pas­cal So­ri­ot’s first full year at the helm of a tot­ter­ing As­traZeneca, he land­ed a pay pack­age worth about $5.5 mil­lion. By

At a time when biotech is still count­ing its loss­es as a thaw grad­u­al­ly sets in af­ter the long mar­ket win­ter, phar­ma has been on

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you

2023 marks one of those years in life sci­ences when ven­ture cap­i­tal spent a lot of time look­ing for ways to pre­serve cash run­ways and